![](https://monteverdelaw.com/wp-content/uploads/case-logo/provention-bio-inc.png)
Provention Bio, Inc. (NASDAQ: PRVB), relating to its proposed sale to Sanofi. Under the terms of the agreement PRVB shareholders are expected to receive $25.00 in cash per share they own.
Provention Bio, Inc. (NASDAQ: PRVB), relating to its proposed sale to Sanofi. Under the terms of the agreement PRVB shareholders are expected to receive $25.00 in cash per share they own.